Search Results for “AstraZeneca” – Page 8 – media

AstraZeneca, Geisinger Come Together to Develop Asthma Care

Pharmaceutical giant AstraZeneca and integrated health services provider Geisinger are partnering to create an app suite, which by connecting to electronic health records (EHR) aims to upgrade asthma care.
- Source: The Verdict
- 918
- July 23, 2018
asthma Company Insight EHR mHealth
Two Approvals for AstraZeneca in Japan

The immunotherapy drug was approved for lung cancer patients with no chance for surgery whose cancer had not yet spread to other parts of the body.
- Source: Reuters
- 1,000
- July 3, 2018
breast cancer Japan lung cancer New Approvals
AstraZeneca’s Durvalumab Receives Go-Ahead from DCGI to Market in India

Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
- Source: United News of India
- 2,553
- June 26, 2018
AstraZeneca cancer India New Approvals
R&D for organ-on-a-chip tech by AstraZeneca and Emulate.

AstraZeneca has collaborated with Emulate integrate an organ-on-a-chip technology into the R&D program of the pharma giant. It is meant to expedite the technology’s development within the company.
- Source: Ddu
- 771
- May 17, 2018
AstraZeneca Researches
AstraZeneca continues yard-sale strategy with $538M Seroquel rights deal

AstraZeneca is back at it again with asset sales. The company, which has taken some flak for a series of deals to offload asset rights, inked an agreement with Luye Pharma for legacy antipsychotic Seroquel and an extended-release version.
- Source: fiercepharma
- 678
- May 10, 2018
AstraZeneca Seroquel
Amid tough respiratory competition, AstraZeneca inks Symbicort outcomes-based deals

It's no secret that respiratory drugs make up a crowded field, and forthcoming generics will make the competition tougher still. AstraZeneca's Symbicort is no stranger to the fallout, either, what with payers pressing prices and new rivals grabbing share.
- Source: fiercepharma
- 635
- April 20, 2018
AstraZeneca Company Insights Symbicor
Ionis and AstraZeneca Advance New Drug for NASH

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH)
- Source: Prnewswire
- 624
- April 11, 2018
Market Views NASH
Adherium receives OTC clearance for AstraZeneca’s Symbicort inhaler

Smart inhaler company Adherium announced last week that it has received 510(k) clearance for over-the-counter sales of its inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler, called the SmartTouch for Symbicort.
- Source: MobiHealthNews
- 802
- April 7, 2018
COPD FDA New Approvals
Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge

The FDA has slapped a clinical hold on a combo therapy using Advaxis’$ADXS axalimogene filolisbac along with AstraZeneca’s approved PD-L1 Imfinzi following the death of a patient in their Phase I/II trial.
- Source: endpts
- 626
- March 15, 2018
AstraZeneca cervical cancer Company Insight FDA
Why AstraZeneca’s New Drug Strategy Seems to be Bearing Fruit

Pharma giant AstraZeneca has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reutersreported Thursday.
- Source: china-pharmacy
- 490
- February 7, 2018
AstraZeneca New Drug Strategy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.